Sidra Medicine welcomes EORTC delegation, headed by HRH Princess Dina Mired of Jordan


Sidra Medicine welcomed a visiting delegation from the European Organisation for Research and Treatment of Cancer (EORTC), headed by HRH Princess Dina Mired of Jordan, Honorary President of EORTC Cancer Research Fund (EORTC/ECRF), and including Count Diego du Monceau de Bergendal, Chairman of ECRF, and Dr Denis Lacombe, CEO of EORTC. The delegation met with Sidra Medicine CEO, Dr. Iyabo Tinubu-Karch; Chief Medical Officer, Prof. Ziyad M. Hijazi and Chief Research Officer, Dr. Khalid Fakhro to discuss mutual collaborations in the field of clinical cancer research and therapy.

Commenting on the visit, the Honorary President of EORTC/ECRF, HRH Princess Dina Mired of Jordan said: "EORTC has been a leading not-for-profit organisation for clinical cancer research for more than six decades significantly improving survival and quality of life of cancer patients. I am delighted to have chaired this delegation of the EORTC to explore strategic partnerships to support our region to embrace clinical research to best serve our patients and push forward the standards of care. Only through such partnerships can our health care providers access state-of-the-art knowledge in the methodology of clinical trials."

CEO of Sidra Medicine, Dr. Iyabo Tinubu-Karch said: “Sidra Medicine has been at the forefront in the Middle East region, regarding several of its pediatric cancer care and clinical research programs. This is a credit to the expertise of our people, the innovative technologies and our ground-breaking services, but also thanks to our local and global collaborative partners. We are looking forward to discussing how the EORTC and Sidra Medicine can join forces to help advance cancer research and therapy. We hope this will be the start of a strong partnership that will help improve the care as well as build on the foundation of personalized treatment for cancer patients worldwide.”